LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

LLY

1,066.82

+2.48%↑

JNJ

234.57

+1.33%↑

ABBV

216.12

+0.45%↑

UNH

388.17

+1.5%↑

AZN

187.25

-1.32%↓

Inicio・Lista de Acciones・Anika Therapeutics Inc

Anika Therapeutics Inc

Cerrado

SectorSanidad

14.85 -0.54

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

14.76

Máximo

14.88

Métricas clave
By Trading Economics
Ingresos	-5.3M -5.1M
Ventas	-1M 30M
BPA	0.27
Margen de beneficios	-17.074
Empleados	235
EBITDA	-6.3M -4.1M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 Meses	+17.61% upside

Dividendos
By Dow Jones
Próximas Ganancias	29 jul 2026

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	-30M 199M
Apertura anterior	15.39
Cierre anterior	14.85

Noticias sobre sentimiento de mercado

By Acuity

50%

159 / 345 Clasificación en Healthcare

Anika Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

25 may 2026, 08:24 UTC

Principales Movimientos del Mercado

Adquisiciones, fusiones, absorciones

Uber's $11.6 Billion Takeover Approach Lifts Delivery Hero Shares

25 may 2026, 21:22 UTC

Ganancias

Disney's 'Mandalorian and Grogu' Conquers Memorial Day Weekend Box Office -- Barrons.com

25 may 2026, 20:50 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:20 UTC

Charlas de Mercado

Ganancias

Basic Materials Roundup: Market Talk

25 may 2026, 16:01 UTC

Charlas de Mercado

China's Crude Imports Pullback Helps Cap Price Upside -- Market Talk

25 may 2026, 14:43 UTC

Charlas de Mercado

Oil Unlikely to Fall Significantly Until Hormuz Fully Reopens -- Market Talk

25 may 2026, 14:15 UTC

Charlas de Mercado

Crude Futures Retreat As U.S.-Iran Progress Toward Deal -- Market Talk

25 may 2026, 13:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

25 may 2026, 12:58 UTC

Charlas de Mercado

Over 60% of Albertans Indicate No Interest in Separation From Canada -- Market Talk

25 may 2026, 12:56 UTC

Charlas de Mercado

Ganancias

Canadian Earnings Lifted by Higher Commodity Prices in Latest Quarter -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Interest-Rate Cuts Unlikely in 2026 Even if Middle East Conflict Ends -- Market Talk

25 may 2026, 12:48 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

25 may 2026, 12:34 UTC

Charlas de Mercado

Dollar Extends Falls on U.S.-Iran Deal Prospects -- Market Talk

25 may 2026, 12:10 UTC

Charlas de Mercado

Adquisiciones, fusiones, absorciones

Delivery Hero's Assets Look Strategic -- Market Talk

25 may 2026, 11:00 UTC

Charlas de Mercado

Euro, Sterling, Riskier Currencies Rise Versus Weaker Dollar -- Market Talk

25 may 2026, 10:19 UTC

Charlas de Mercado

Swiss Franc Rises to Highest in More Than Two Months Vs Euro -- Market Talk

25 may 2026, 10:05 UTC

Ganancias

Tenaga Nasional: Well-Positioned to Navigate Global Geopolitical Uncertainties

25 may 2026, 10:04 UTC

Ganancias

Tenaga Nasional: Operational Performance to Remain Resilient in 2026

25 may 2026, 10:03 UTC

Ganancias

Tenaga Nasional: 1Q Operating Profit Rose on Higher Electricity Demand, Lower Fuel Prices

25 may 2026, 10:02 UTC

Ganancias

Tenaga Nasional: 1Q Rev Rose on Higher Electricity Sales

25 may 2026, 10:01 UTC

Ganancias

Tenaga Nasional 1Q Net Up 3.7% on Year

25 may 2026, 10:00 UTC

Ganancias

Tenaga Nasional 1Q Rev Up 6.6% on Year

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional Malaysia 1st-Quarter 2026 Earnings Summary Table

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q EPS MYR0.1883

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Rev MYR17.1B

25 may 2026, 09:56 UTC

Ganancias

Tenaga Nasional 1Q Net MYR1.1B

25 may 2026, 09:38 UTC

Charlas de Mercado

U.S.-Iran Talks Lifted Sentiment But No Agreement Would Quickly Restore Normal Market Conditions -- Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

25 may 2026, 09:33 UTC

Charlas de Mercado

India's Gold Import Tax Raise Won't Curb Demand -- Market Talk

25 may 2026, 08:55 UTC

Charlas de Mercado

European Energy Stocks Slide on Falling Oil Prices -- Market Talk

Comparación entre iguales

Cambio de precio

Anika Therapeutics Inc previsión

Precio Objetivo

By TipRanks

17.61% repunte

Estimación a 12 Meses

Media 17.5 USD 17.61%

Máximo 18 USD

Mínimo 17 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Anika Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Anika Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

159 / 345 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Anika Therapeutics Inc

Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.